Sarepta Therapeutics (NASDAQ:SRPT) Price Target Raised to $213.00

Sarepta Therapeutics (NASDAQ:SRPTFree Report) had its price objective hoisted by Bank of America from $166.00 to $213.00 in a research report released on Friday morning, Benzinga reports. Bank of America currently has a buy rating on the biotechnology company’s stock.

Several other research firms also recently weighed in on SRPT. Wedbush reissued an outperform rating and issued a $224.00 price target on shares of Sarepta Therapeutics in a research note on Thursday, February 29th. Royal Bank of Canada raised their price target on shares of Sarepta Therapeutics from $142.00 to $182.00 and gave the stock a sector perform rating in a research note on Friday. TheStreet raised shares of Sarepta Therapeutics from a d rating to a c- rating in a research note on Monday, March 4th. Barclays lifted their target price on shares of Sarepta Therapeutics from $141.00 to $185.00 and gave the stock an overweight rating in a research note on Thursday, February 29th. Finally, BMO Capital Markets reaffirmed an outperform rating and set a $170.00 target price on shares of Sarepta Therapeutics in a research note on Friday, June 14th. Four equities research analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the company’s stock. According to MarketBeat.com, Sarepta Therapeutics presently has an average rating of Moderate Buy and a consensus target price of $177.65.

Get Our Latest Stock Report on SRPT

Sarepta Therapeutics Stock Performance

SRPT opened at $160.72 on Friday. The firm’s fifty day simple moving average is $125.56 and its two-hundred day simple moving average is $120.18. The company has a quick ratio of 3.44, a current ratio of 4.05 and a debt-to-equity ratio of 1.18. The company has a market cap of $15.19 billion, a price-to-earnings ratio of 1,461.09 and a beta of 0.96. Sarepta Therapeutics has a 52-week low of $55.25 and a 52-week high of $173.25.

Sarepta Therapeutics (NASDAQ:SRPTGet Free Report) last posted its quarterly earnings results on Wednesday, May 1st. The biotechnology company reported $0.73 earnings per share for the quarter, topping the consensus estimate of ($0.11) by $0.84. The firm had revenue of $413.50 million for the quarter, compared to the consensus estimate of $375.52 million. Sarepta Therapeutics had a net margin of 1.20% and a return on equity of 2.20%. The company’s revenue for the quarter was up 63.1% on a year-over-year basis. During the same period last year, the firm posted ($1.44) earnings per share. Equities analysts anticipate that Sarepta Therapeutics will post 2.99 earnings per share for the current fiscal year.

Insider Activity at Sarepta Therapeutics

In related news, insider Dallan Murray sold 3,635 shares of Sarepta Therapeutics stock in a transaction that occurred on Thursday, May 2nd. The shares were sold at an average price of $140.00, for a total value of $508,900.00. Following the completion of the transaction, the insider now owns 18,125 shares in the company, valued at $2,537,500. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 7.70% of the company’s stock.

Institutional Trading of Sarepta Therapeutics

Institutional investors have recently modified their holdings of the stock. GAMMA Investing LLC raised its position in Sarepta Therapeutics by 37.0% in the 1st quarter. GAMMA Investing LLC now owns 322 shares of the biotechnology company’s stock valued at $42,000 after purchasing an additional 87 shares during the last quarter. Vanguard Capital Wealth Advisors raised its position in Sarepta Therapeutics by 3.8% in the 4th quarter. Vanguard Capital Wealth Advisors now owns 2,450 shares of the biotechnology company’s stock valued at $236,000 after purchasing an additional 90 shares during the last quarter. Riggs Asset Managment Co. Inc. raised its position in Sarepta Therapeutics by 125.0% in the 1st quarter. Riggs Asset Managment Co. Inc. now owns 225 shares of the biotechnology company’s stock valued at $29,000 after purchasing an additional 125 shares during the last quarter. WCM Investment Management LLC raised its position in Sarepta Therapeutics by 2.3% in the 1st quarter. WCM Investment Management LLC now owns 6,279 shares of the biotechnology company’s stock valued at $813,000 after purchasing an additional 142 shares during the last quarter. Finally, Cary Street Partners Investment Advisory LLC raised its position in Sarepta Therapeutics by 154.0% in the 3rd quarter. Cary Street Partners Investment Advisory LLC now owns 254 shares of the biotechnology company’s stock valued at $31,000 after purchasing an additional 154 shares during the last quarter. Hedge funds and other institutional investors own 86.68% of the company’s stock.

Sarepta Therapeutics Company Profile

(Get Free Report)

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.

Read More

Analyst Recommendations for Sarepta Therapeutics (NASDAQ:SRPT)

Receive News & Ratings for Sarepta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.